Clinical Trials Logo

Chemotherapy Effect clinical trials

View clinical trials related to Chemotherapy Effect.

Filter by:

NCT ID: NCT05429814 Completed - Breast Cancer Clinical Trials

Topical Menthol Application in Chemotherapy-Related Peripheral Neuropathy in Patients With Breast Cancer

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Peripheral neuropathy resulting from chemotherapy is a problem that concerns not only the individual but also their relatives and all healthcare personnel responsible for care. Studies to be carried out in this area are important in terms of providing evidence for nurses' practices and supporting the individual by alleviating the symptoms of the disease. Based on this information, the aim of this study is to determine the effect of menthol application, which will be applied to the hands and feet of breast cancer patients receiving chemotherapy, on CIPN.

NCT ID: NCT05350930 Completed - Chemotherapy Effect Clinical Trials

Multidisciplinary Care Program to Secure mEdication Therapy for hematoLOgy Patients Receiving Injectable Anticancer Drugs

Melodia
Start date: June 9, 2022
Phase:
Study type: Observational

Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations. This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare

NCT ID: NCT05175066 Completed - Chemotherapy Effect Clinical Trials

Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity

Start date: November 12, 2020
Phase: Phase 3
Study type: Interventional

Anthracyclines are one of the most well-known and effective drugs used to treat malignancies.The most important limiting factor in the use of this drug is its cardiac toxicity which includes cardiomyopathy and congestive heart failure. Bisoprlol is a β1-specific β-blocker that can reduce cardiac overload and also have anti-inflammatory antioxidant effects and can reduce reactive oxygen metabolites so it can be used as a cardioprotective agent in patients with a high risk of heart failure. To the best of our knowledge, no study has been performed to evaluate the prophylactic effect of bisoprolol solely in patients under chemotherapy with anthracyclines. This study is aimed to evaluate the cardioprotective role of bisoprolol in patients with non-metastatic breast cancer receiving doxorubicin, by measuring global longitudinal strain before and after treatment.

NCT ID: NCT05131490 Completed - Gynecologic Cancer Clinical Trials

Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients

Start date: September 15, 2022
Phase: N/A
Study type: Interventional

Getting a cancer diagnosis, the difficult treatments applied and the side effects that occur completely affect the life of the patient, shaking his future plans and adaptation mechanisms. In recent years, the role of healthcare professionals has included counseling and promoting positive health behaviors to reduce disease and treatment side effects and increase adherence to disease. The service provided by healthcare professionals to patients has started to move to digital environments with the developing technology and the concept of e-health has been born. Offering e-health support as part of regular care has become a powerful tool to help cancer patients manage their disease. Web-based interventions or mobile applications provide an opportunity for improved communication and better information exchange between healthcare professionals and patients. In addition, education of cancer patients and patient self-management allow for better clinical outcomes using e-health or mobile health applications. The widespread use of smartphones enables cancer patients to be supported from different perspectives through mobile applications. When the studies are examined, it is noteworthy that mobile applications developed for female cancer patients are predominantly related to breast cancer. Most of the technology-based researches on gynecological cancers are studies conducted through text message intervention, online web-based interventions or social media tools such as Facebook and WeChat. For this reason, the aim of this study is to develop a mobile application to increase physical and psychosocial adjustment for gynecological cancer patients receiving chemotherapy and to investigate its effectiveness.

NCT ID: NCT04882371 Completed - Breast Cancer Clinical Trials

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Start date: January 1, 2018
Phase:
Study type: Observational

The current study aims to determine the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography- Computed Tomography (PET-CT) in predicting a pathological response of molecular subtypes of breast cancer to neoadjuvant chemotherapy (NAC).

NCT ID: NCT04874584 Completed - Quality of Life Clinical Trials

Culturally Tailored Nurse Coaching Study for Cancer Symptom Management

Start date: October 27, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to see whether or not a telephone/ text message intervention, delivered by a registered nurse, is helpful in managing symptoms and can also prevent dehydration caused by chemotherapy treatment when given together for patients with metastatic breast, colon, lung or prostate cancer.

NCT ID: NCT04770623 Completed - Gastric Cancer Clinical Trials

Docetaxel and Irinotecan in Gastric Cancer

Start date: March 5, 2021
Phase: Phase 2
Study type: Interventional

To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.

NCT ID: NCT04769414 Completed - Chemotherapy Effect Clinical Trials

Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)

Start date: February 20, 2021
Phase: Phase 2
Study type: Interventional

In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment. This regimen is expected to be less toxic than FOLFIRINOX and aiming at better outcomes.

NCT ID: NCT04755140 Completed - Heart Diseases Clinical Trials

Endoprosthesis Metal Toxicity Study

Start date: March 19, 2021
Phase:
Study type: Observational

The purpose of this research is to investigate whether patients who previously had endoprosthesis surgery experience memory, thinking, or heart problems. It will also help determine how often these problems occur.

NCT ID: NCT04694794 Completed - Chemotherapy Effect Clinical Trials

Diminish Chemotherapy Related Side Effects Through Patient Education

D-CRSE
Start date: March 24, 2021
Phase: N/A
Study type: Interventional

Currently, there is a lack of patient education materials regarding cytotoxic chemotherapy side effects, research supported treatments, and the utilization of CAM by cancer patients at Penn State Cancer Institute. The investigators aim to develop an educational brochure, which educates patients about the chemotherapy side effects they may experience, and provide them with the tools to address the problem themselves, know when to contact their medical oncologist, and understand when it is appropriate to go to the Emergency Department. By educating patients regarding these problems, patient anxiety may decrease, the number of calls into the oncologist office may decrease, and Emergency Department visits may decrease, which would decrease costs for the patient, the hospital, and the health system. If this intervention is found to be useful and impactful, it can be further utilized within the Cancer Institute by other disease teams, by other Penn State institutions, or by other institutions across the country.